Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948984 | 0.99 | POLB (0.65) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL6753966 | 0.96 | POLB (0.64) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL4110878 | 0.90 | LMNA (0.64) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL6757232 | 0.88 | LMNA (0.62) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL5792173 | 0.83 | POLB (0.62) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL6759257 | 0.82 | IDO1 (0.68) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL7006523 | 0.82 | POLB (1.00) | POLBNPC1RAB9A | |
| SCHEMBL4111972 | 0.81 | IDO1 (0.70) | POLBLMNANPC1RAB9AIDO1 | |
| SCHEMBL7854826 | 0.80 | POLB (0.96) | POLBNPC1RAB9AKDM4E | |
| SCHEMBL7856315 | 0.80 | POLB (0.96) | POLBNPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020654-A1 | Novel PPAR agonists, pharmaceutical compositions and uses thereof | BETHESDA PHARMACEUTICALS, INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004082621-A2 | NOVEL PPAR AGONISTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BETHESDA PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| EP-0791671-B1 | Surface treating agent for copper or copper alloy | SHIKOKU CHEM (JP) | 1999-06-16 | — | — | EP | disclosed |
| US-5795409-A | MIXTURE OF A (BENZ)IMIDAZOLE COMPOUND, CHELATE COMPOUND AND IRON | SHIKOKU CHEMICALS CORPORATION (JP) | 1998-08-18 | — | — | US | disclosed |
| EP-0791671-A1 | Surface treating agent for copper or copper alloy | SHIKOKU CHEMICALS CORPORATION (JP) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020654-A1 | Novel PPAR agonists, pharmaceutical compositions and uses thereof | PPARG, PPARD, PPARA | POLB 3623/4885LMNA 3776/4885NPC1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.